Dong-A ST Presents Non-clinical Research on GPX4 Activator and Tau Aggregation Inhibitor at AAIC

“Committed to Innovative Drug Development for Neurodegenerative Diseases”

Dong-A ST announced on July 15 that it presented non-clinical research results on the GPX4 activator 'DA-7505' and the tau aggregation inhibitor 'DA-7503' through poster sessions at the Alzheimer's Association International Conference (AAIC), which took place in London, UK, from July 12 to July 15 (local time).

Dong-A ST introduced the research results of DA-7505 under the theme "Improvement of Cognitive Decline via Inhibition of Ferroptosis and Neuroinflammation by a Novel GPX4-Positive Allosteric Modulator."

A researcher from Dong-A ST is presenting a poster to attendees at the American Association for the Advancement of Science (AAIC) conference. Dong-A ST

The study found that DA-7505 binds to GPX4 within nerve cells, enhances its catalytic activity, and effectively suppresses cell death caused by lipid peroxidation and ferroptosis by preventing protein degradation under ferroptotic conditions. Notably, it demonstrated superior anti-inflammatory effects compared to conventional inhibitors based on reactive oxygen species (ROS) elimination mechanisms.

Additionally, under the theme "Evaluation of the Efficacy of the Tau Aggregation Inhibitor DA-7503 Alone and in Combination with Lecanemab in Models of Tauopathy and Alzheimer's Disease," Dong-A ST also presented the research results of DA-7503.

In a tauopathy mouse model, DA-7503 significantly improved cognitive and motor functions even at low doses. These effects increased in a dose-dependent manner, and DA-7503 inhibited the hyperphosphorylation and oligomerization of tau protein across the cerebral cortex and hippocampus, significantly reducing tau aggregation and accumulation to effectively ameliorate overall tau pathology.

Furthermore, in an Alzheimer's disease model, DA-7503, when administered together with lecanemab—a standard amyloid-beta targeting antibody therapy—further improved key pathological markers, including tau and amyloid-beta, beyond what was achieved with standard therapy alone.

A representative at Dong-A ST stated, "Through these research results, we have once again demonstrated the therapeutic potential of DA-7503 and DA-7505 for degenerative brain diseases. We will continue research aimed at developing next-generation therapeutic agents targeting various disease mechanisms in tauopathy and Alzheimer's disease, and remain committed to innovating drug development for neurodegenerative disorders with high unmet medical needs."

This content was produced with the assistance of AI translation services.